Overview

Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage -B EGFR Sensitive Mutanted NSCLC

Status:
NOT_YET_RECRUITING

Trial end date:
2027-12-01

Target enrollment:

Participant gender:

Summary

This is a phase II study aimed to assess the efficacy and safety of firmonertinib combined with carboplatin/cisplatin and pemetrexed as neoadjuvant therapy in stage II-IIIB resectable NSCLC patients.

Phase:

PHASE2

Details

Lead Sponsor:

Tianjin Medical University Cancer Institute and Hospital

Treatments:

Carboplatin
Cisplatin
Pemetrexed